Search

Search Results

• NOVEL AGENTS AND EMERGING STRATEGIES FOR TARGETING THE B-CELL RECEPTOR PATHWAY IN CLL

  Dimitar Efremov, Adrian Wiestner, Luca Laurenti

  e2012067

  2012-10-09

  https://doi.org/10.4084/mjhid.2012.067

  2502

  PDF: 839

  HTML: 8866

  Efremov 1: 227

  Efremov 2: 191

• TYROSINE KINASE INHIBITORS AND INTERFERON

  Maria Dimou, Panagiotis Panagiotidis

  e2014006

  2014-01-02

  https://doi.org/10.4084/mjhid.2014.006

  2859

  PDF: 1437

  HTML: 3045

  Cover Letter: 208

• SECOND-GENERATION TYROSINE KINASE INHIBITORS (TKI) AS SALVAGE THERAPY FOR RESISTANT OR INTOLERANT PATIENTS TO PRIOR TKIs

  Massimo Breccia, Giuliana Alimena

  e2014003

  2014-01-02

  https://doi.org/10.4084/mjhid.2014.003

  3151

  PDF: 1220

  HTML: 3470

• TYROSINE KINASE INHIBITORS AND PREGNANCY

  Elisabetta Abruzzese, Malgorzata Monika Trawinska, Paolo De Fabritiis, Alessio Pio Perrotti

  e2014028

  2014-04-07

  https://doi.org/10.4084/mjhid.2014.028

  3573

  PDF: 1639

  HTML: 2674

• BRUTON’S TYROSINE KINASE (BTK) MUTATIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): A CLINICAL VIEW.

  Stefano Molica

  e2025053

  2025-06-29

  https://doi.org/10.4084/MJHID.2025.053

  1583

  PDF: 909

  HTML: 121

• TREATMENT RECOMMENDATIONS FOR CHRONIC MYELOID LEUKEMIA

  Michele Baccarani, Fausto Castagnetti, Gabriele Gugliotta, Francesca Palandri, Gianantonio Rosti

  e2014005

  2014-01-02

  https://doi.org/10.4084/mjhid.2014.005

  3332

  PDF: 1470

  HTML: 4003

• MONITORING THE RESPONSE TO TYROSINE KINASE INHIBITOR (TKI) TREATMENT IN CHRONIC MYELOID LEUKEMIA (CML)

  Ibrahim C. Haznedaroglu

  e2014009

  2013-12-31

  https://doi.org/10.4084/mjhid.2014.009

  3942

  PDF: 1505

  HTML: 9188

  Untitled: 278

  Untitled: 184

  Untitled: 169

  Untitled: 164

  Untitled: 181

  Untitled: 339

• SYSTEMIC MASTOCYTOSIS: MOLECULAR LANDSCAPE AND IMPLICATIONS FOR TREATMENT

  Cecilia Monaldi, Sara De Santis, Manuela Mancini, Samantha Bruno, Michele Cavo, Simona Soverini

  e2021046

  2021-06-28

  https://doi.org/10.4084/MJHID.2021.046

  1395

  PDF: 690

  HTML: 284

• BCR SIGNALING INHIBITORS: AN OVERVIEW OF TOXICITIES ASSOCIATED WITH IBRUTINIB AND IDELALISIB IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA

  Lorenzo Falchi, Jessica M Baron, Carrie Anne Orlikowski, Alessandra Ferrajoli

  e2016011

  2016-02-10

  https://doi.org/10.4084/mjhid.2016.011

  4305

  PDF: 1483

  HTML: 3619

• DRUG THERAPY IN THE PROGRESSED CML PATIENT WITH MULTI-TKI FAILURE

  Ibrahim C. Haznedaroglu

  e2015014

  2015-12-02

  https://doi.org/10.4084/mjhid.2015.014

  277660

  PDF: 1792

  HTML: 3870

• IMATINIB IN CHRONIC MYELOID LEUKEMIA: AN OVERVIEW

  Tomasz Sacha

  e2014007

  2013-12-31

  https://doi.org/10.4084/mjhid.2014.007

  4765

  PDF: 2838

  HTML: 2288

• OCCURRENCE OF SECONDARY MALIGNANCIES IN CHRONIC MYELOID LEUKEMIA DURING THERAPY WITH IMATINIB MESYLATE-SINGLE INSTITUTION EXPERIENCE

  Grzegorz Helbig, Grazyna Bober, Marek Seweryn, Ryszard Wichary, Andrzej Tukiendorf, Lech Sedlak, Tomasz Oleksy, Slawomira Kyrcz-Krzemien

  e2015003

  2015-01-01

  https://doi.org/10.4084/mjhid.2015.003

  2221

  PDF: 1046

  HTML: 1984

  Characteristic of study group: 199

• OPTIMIZING TREATMENT, MINIMIZING RISK: THERAPEUTIC DRUG MONITORING IN HEMATOLOGICAL MALIGNANCIES

  Jon Salmanton-Garcia, Francesco Marchesi, Oliver A. Cornely, Jannik Stemler, Pierantonio Menna

  2026-02-28

  https://doi.org/10.4084/MJHID.2026.022

  1070

  PDF: 1256

  Suppl. Files: 146

  HTML: 70

• Pathogenetic mechanism of macular edema during a treatment with ibrutinib: a case presentation.

  Cristina Mauro, Livio Pupo, Lucia Cardillo, Fabiana Esposito, Elisa Buzzatti, Marco Lombardo, Massimo Cesareo, Adriano Venditti, Massimiliano Postorino, Maria Ilaria Del Principi

  e2026009

  2026-01-01

  https://doi.org/10.4084/MJHID.2026.009

  559

  PDF: 439

  Html: 294

• TP53-MUTATED MYELODYSPLASIA AND ACUTE MYELOID LEUKEMIA TP53 in MDS and AML

  Ugo Testa, Dr. Germana Castelli, Dr. Elvira Pelosi

  e2023038

  2023-06-29

  https://doi.org/10.4084/MJHID.2023.038

  2132

  PDF: 1696

  HTML: 378

• THE GROWING ROLE OF THE BH3 MIMETIC DRUG VENETOCLAX IN THE THERAPY OF ACUTE MYELOID LEUKEMIA

  Elvira Pelosi, Dr. Germana Castelli, Ugo Testa

  e2022080

  2022-10-29

  https://doi.org/10.4084/MJHID.2022.080

  1487

  PDF: 1148

  HTML: 276

• Evaluation of Hepatitis B and C Reactivation in Chronic Myeloid Leukemia Patients Treated with Tyrosine Kinase Inhibitors

  Nathalia Sena de Oliveira Silva, Gislaine Duarte, Samuel de Souza Medina, Guilherme Brasil Duffles Amarante, Carmino Antonio de Souza, Katia Borgia Barbosa Pagnano

  e2026001

  2026-01-01

  https://doi.org/10.4084/MJHID.2026.001

  662

  PDF: 474

  Html: 79

• GILTERITINIB (XOSPATA ®) IN TURKEY: EARLY ACCESS PROGRAM RESULTS Gilteritinib (XOSPATA ®) in Turkey

  Mehmet Hilmi DOGU, Ali Irfan Emre TEKGUNDUZ, Burak DEVECI, Gulten KORKMAZ, Melda COMERT, Omur Gokmen SEVINDIK, Osman YOKUS, Istemi SERIN

  e2023031

  2023-04-28

  https://doi.org/10.4084/MJHID.2023.031

  1422

  PDF: 904

  Suppl. Files: 455

  HTML: 237

• ROLE OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ADULT PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA

  Federico Lussana, Alessandro Rambaldi

  e2014065

  2014-10-20

  https://doi.org/10.4084/mjhid.2014.065

  2872

  PDF: 1235

  HTML: 2698

  Figure 1: 173

• PROGNOSTIC SIGNIFICANCE OF TRANSCRIPT-TYPE BCR/ABL1 IN CHRONIC MYELOID LEUKEMIA

  matteo molica, elisabetta abruzzese, massimo breccia

  e2020062

  2020-09-12

  https://doi.org/10.4084/mjhid.2020.062

  3630

  PDF: 1592

  HTML: 634

• Breastfeeding in patients with chronic myeloid leukaemia: case series with measurements of drug concentrations in maternal milk and review of literature

  Ekaterina Chelysheva, Sergey Aleshin, Evgenia Polushkina, Roman Shmakov, Igor Shokhin, Ghermes Chilov, Anna Turkina

  e2018027

  2018-05-01

  https://doi.org/10.4084/mjhid.2018.027

  3170

  PDF: 988

  HTML: 357

• TREATMENT OF INDOLENT AND ADVANCED SYSTEMIC MASTOCYTOSIS Systemic Mastocytosis Treatment

  Alessandro Buonomo, Eleonora Nucera, Marianna Criscuolo

  e2022040

  2022-04-28

  https://doi.org/10.4084/MJHID.2022.040

  2089

  PDF: 1524

  HTML: 285

• FLT3 INTERNAL TANDEM DUPLICATION AND D835 MUTATIONS IN PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA AND ITS CLINICAL SIGNIFICANCE

  Ghaleb Elyamany, Mohamed Awad, Omar Alsuhaibani, Kamal Fadalla, Omer Al Sharif, Mohammad Al Shahrani, Fahad Alabbas, Abdulaziz Al-Abulaaly

  e2014038

  2014-05-30

  https://doi.org/10.4084/mjhid.2014.038

  1815

  PDF: 971

  HTML: 7167

• WALDENSTRÖM MACROGLOBULINEMIA - A STATE-OF-THE-ART REVIEW: PART 2- FOCUS ON THERAPY

  Michele Bibas, Shayna Sarosiek , Jorge Castillo

  e2025015

  2025-02-27

  https://doi.org/10.4084/MJHID.2025.015

  2526

  PDF: 1996

  HTML: 206

• THE Co-Occurrence of Jak2/Calr-Positive Myeloproliferative Disorder and Bcr-Abl-Positive Chronic Myelogenous Leukaemia Treated with Combination of Tyrosine Kinase Inhibitors and Ruxolitinib. Dual Myeloid Disorder Treated with Two Drug Association

  Katia Paciaroni, Selenia Campagna, Nicoletta Villiva', Enrico Maffini, Francesca Celesti, Attilio Tordi, Mariangela Lombardi, Giulia Dragonetti, Tommaso Caravita di Toritto

  e2025023

  2025-02-27

  https://doi.org/10.4084/MJHID.2025.023

  1060

  PDF: 1061

  HTML: 97

• TRANSCRIPTOME ANALYSIS OF BETA-CATENIN-RELATED GENES IN CD34+ HAEMATOPOIETIC STEM AND PROGENITOR CELLS FROM PATIENTS WITH AML Transcriptome analysis of beta-catenin-related genes in AML

  Buket Altinok Gunes, Tulin OZKAN, Aynur Karadag Gurel, Semih Dalkilic, Nevin Belder, Zeynep Ozkeserli, Hilal Ozdag Sevgili, Meral Beksac, Nilgun Sayinalp, Abdullah Munci Yagci, Asuman Sunguroglu

  e2024058

  2024-06-29

  https://doi.org/10.4084/MJHID.2024.058

  1045

  PDF: 1159

  Suppl. Files: 569

  HTML: 88

• INVASIVE FUNGAL INFECTIONS IN PATIENTS WITH CHRONIC LYMPHOPROLIFERATIVE DISORDERS IN THE ERA OF TARGET DRUGS

  Livio Pagano, Davide Facchinelli, Dr.

  e2018063

  2018-10-27

  https://doi.org/10.4084/mjhid.2018.063

  2048

  PDF: 1118

  HTML: 213

• WALDENSTRÖM MACROGLOBULINEMIA - A STATE-OF-THE-ART REVIEW: PART 1: EPIDEMIOLOGY, PATHOGENESIS, CLINICOPATHOLOGIC CHARACTERISTICS, DIFFERENTIAL DIAGNOSIS, RISK STRATIFICATION, AND CLINICAL PROBLEMS

  Michele Bibas, Shayna Sarosiek, Jorge J. Castillo

  e2024061

  2024-06-29

  https://doi.org/10.4084/MJHID.2024.061

  2759

  PDF: 3212

  HTML: 379

• ROLE OF STEM CELL FACTOR IN THE REACTIVATION OF HUMAN FETAL HEMOGLOBIN

  Marco Gabbianelli, Ugo Testa

  e2009009

  2009-11-12

  1122

  PDF: 477

  HTML: 4480

• SARS-CoV-2 (COVID-19) and Chronic Myeloid Leukemia (CML): a case report and review of ABL kinase involvement in viral infection CML and COVID-19

  Elisabetta Abruzzese, Luigia Luciano, Francesco D'Agostino, Malgorzata Monika Trawinska, Fabrizio Pane, Paolo de Fabritiis

  e2020031

  2020-04-27

  https://doi.org/10.4084/mjhid.2020.031

  3266

  PDF: 1535

  HTML: 432

• NOVEL DRUGS IN FOLLICULAR LYMPHOMA

  Giuseppe Rossi, Antonella Anastasia

  e2016061

  2016-11-01

  https://doi.org/10.4084/mjhid.2016.061

  4325

  PDF: 1491

  HTML: 1549

  Untitled: 225

• SYSTEMIC MASTOCYTOSIS: MULTIDISCIPLINARY APPROACH Systemic Mastocytosis

  Roberta Zanotti, Massimiliano Bonifacio, Ilaria Tanasi, Donatella Schena, Giovanni Orsolini, Morena Tebaldi, Lara Crosera, Francesca Mastropaolo, Elisa Olivieri, Dr. Patrizia Bonadonna

  e2021068

  2021-10-29

  https://doi.org/10.4084/MJHID.2021.068

  1533

  PDF: 944

  HTML: 223

• DIAGNOSIS AND SUBCLASSIFICATION OF ACUTE LYMPHOBLASTIC LEUKEMIA

  Sabina Chiaretti, Gina Zini, Renato Bassan

  e2014073

  2014-10-24

  https://doi.org/10.4084/mjhid.2014.073

  9074

  PDF: 6061

  HTML: 87959

  Fig.1b: 185

  Fig.1c: 190

  Fig.2a: 177

  Fig.2b: 176

  Fig.4: 188

  Fig.2c: 185

  Fig.3: 182

  Tab.1: 228

  Tab.2: 207

  Tab.3: 189

  Tab.4: 221

  Fig1a: 186

• POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDERS: ROLE OF VIRAL INFECTION, GENETIC LESIONS AND ANTIGEN STIMULATION IN THE PATHOGENESIS OF THE DISEASE

  Daniela Capello, Gianluca Gaidano

  e2009018

  https://doi.org/10.4084/mjhid.2009.018

  1245

  PDF: 475

  HTML: 18600

  Figure 1: 170

  Figure 2: 151

  Figure 3: 169

  Figure 4: 206

  Figure 5: 177

• Successful planned pregnancy through vitrified-warmed embryo transfer in a woman with chronic myeloid leukemia: case report and literature review

  Toshifumi Takahashi

  e2020005

  2020-01-01

  https://doi.org/10.4084/mjhid.2020.005

  1765

  PDF: 1218

  HTML: 309

• SOCIAL AND FINANCIAL BARRIERS TO OPTIMUM TKI TREATMENT IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA- A KNOWLEDGE-ATTITUDES-PRACTICES STUDY FROM INDIA

  Naveen Gupta, Manoranjan Mahapatra, Tulika Seth, Seema Tyagi, Sudha Sazawal, Renu Saxena

  e2021004

  2021-01-01

  https://doi.org/10.4084/mjhid.2021.004

  1717

  PDF: 531

  HTML: 245

• NPM1 MUTATED, BCR-ABL1 POSITIVE MYELOID NEOPLASMS: REVIEW OF LITERATURE NPM1 mutated, BCR-ABL1 positive myeloid neoplasms

  Gianfranco Catalano, Pasquale Niscola, Cristina Banella, Daniela Diverio, Malgorzata Monika Trawinska , Stefano Fratoni, Rita Iazzoni, Paolo de Fabritiis, Elisabetta abruzzese, Nelida Ines Noguera

  e2020083

  2020-10-27

  https://doi.org/10.4084/mjhid.2020.083

  1669

  PDF: 1179

  HTML: 221

• TREATMENT OF ADVANCED SYSTEMIC MASTOCYTOSIS WITH MIDOSTAURIN: PRACTICAL GUIDANCE FOR OPTIMAL THERAPY AND MANAGEMENT Advanced systemic mastocytosis and midostaurin

  Cristina Papayannidis, Vincenzo Federico, Luana Fianchi, Patrizia Pregno, Novella Pugliese, Alessandra Romano, Federica Irene Grifoni

  e2022073

  2022-10-29

  https://doi.org/10.4084/MJHID.2022.073

  1244

  PDF: 996

  HTML: 211

• Validation of a New Scoring System for Treatment Failure in CML Patients on Tyrosine Kinase Inhibitors in a real world setting

  Andrea Mattozzi, Eugenio Galli, Francesco Autore, Ilaria Pansini, Patrizia Chiusolo, Simona Sica, Federica Sorà

  e2026013

  2026-01-01

  https://doi.org/10.4084/MJHID.2026.013

  574

  PDF: 483

  Html: 77

• A CRITICAL HISTORY OF CHRONIC MYELOID LEUKEMIA

  Michele Baccarani, Fabrizio Pane

  e2014010

  2013-12-31

  https://doi.org/10.4084/mjhid.2014.010

  3239

  PDF: 1335

  HTML: 4131

• BLINATUMOMAB IN THE THERAPY OF ACUTE B-LYMPHOID LEUKEMIA BLINATUMOMAB and ALL

  Ugo Testa, Elvira Pelosi, Germana Castelli, Patrizia Chiusolo

  e2024070

  2024-08-31

  https://doi.org/10.4084/MJHID.2024.070

  1636

  PDF: 1093

  HTML: 119

• Mild clinical course of COVID-19 infection in chronic myeloid leukemia (CML) patients receiving tyrosine kinase inhibitors (TKIs) without interruption

  Judit Demeter, Julia Weisinger, Zsolt Nagy

  e2021022

  2021-02-26

  https://doi.org/10.4084/mjhid.2021.022

  1406

  PDF: 483

  HTML: 226

• CD146 MOLECULE EXPRESSION IN B CELLS ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALLs): A FLOW- CYTOMETRIC MARKER FOR AN ACCURATE DIAGNOSTIC WORK-UP

  Alessandro Laganà, Matteo Totaro, Maria Laura Bisegna, Loredana Elia, Stefania Intoppa, Marco Beldinanzi, Mabel Matarazzo, Mariangela di Trani, Alessandro Costa, Raffaele Maglione, Biancamaria Mandelli, Sabina Chiaretti, Maurizio Martelli, Maria Stefania De Propris

  e2024064

  2024-08-31

  https://doi.org/10.4084/MJHID.2024.064

  1309

  PDF: 800

  Suppl. Files: 459

  Html: 108

• ELOTUZUMAB FOR THE TREATMENT OF RELAPSED OR REFRACTORY MULTIPLE MYELOMA, WITH SPECIAL REFERENCE TO ITS MODES OF ACTION AND SLAMF7 SIGNALING

  Masafumi Taniwaki, Mihoko Yoshida, Yosuke Matsumoto, Kazuho Shimura, Junya Kuroda, Hiroto Kaneko

  e2018014

  2018-02-15

  https://doi.org/10.4084/mjhid.2018.014

  5264

  PDF: 1921

  HTML: 1360

• VIRAL CIRRHOSIS: AN OVERVIEW OF HAEMOSTATIC ALTERATIONS AND CLINICAL CONSEQUENCES

  Francesca Romana Ponziani, Valerio De Stefano, Antonio Gasbarrini

  e2009033

  2009-12-29

  https://doi.org/10.4084/mjhid.2009.033

  2618

  PDF: 508

  HTML: 3460

• CAR-T CELLS IN CHRONIC LYMPHOCYTIC LEUKEMIA CAR-T and CLL

  Ugo Testa, Dr. Elvira Pelosi, Dr. Germana Castelli, Dr. Alberto Fresa, Prof. Luca Laurenti

  e2024045

  2024-04-30

  https://doi.org/10.4084/MJHID.2024.045

  3559

  PDF: 1578

  HTML: 80

• IS ALLOGENEIC TRANPLANTATION AN OPTION IN PATIENTS AFFECTED BY CONCURRENT MYELOFIBROSIS AND CHRONIC MYELOID LEUKEMIA (CML)?

  Federica Sorà, Patrizia Chiusolo, Francesco autore, Sabrina Giammarco, luca laurenti, elisabetta metafuni, idanna innocenti, eugenio galli, andrea bacigalupo, simona sica

  e2021062

  2021-10-29

  https://doi.org/10.4084/MJHID.2021.062

  1222

  PDF: 465

  HTML: 157

• Isavuconazole therapy of disseminated and encephalic Saprochaete capitata infection in an acute myeloid leukemia patient treated with midostaurin.

  Salvatore Perrone, Chiara Lisi, Elettra Ortu La Barbera, Cristina Luise, Miriam Lichtner, Corrado Girmenia, Giuseppe Cimino

  e2020026

  2020-04-27

  https://doi.org/10.4084/mjhid.2020.026

  1446

  PDF: 804

  HTML: 319

• AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR HIGH-RISK ACUTE LYMPHOBLASTIC LEUKEMIA: NON-RANDOMIZED STUDY WITH A MAXIMUM FOLLOW-UP OF MORE THAN 22 YEARS

  Grzegorz Helbig, Malgorzata Krawczyk-Kulis, Malgorzata Kopera, Krystyna Jagoda, Patrycja Rzepka, Aleksandra Majewska-Tessar, Marta Hejla, Slawomira Kyrcz-Krzemien

  e2014047

  2014-06-29

  https://doi.org/10.4084/mjhid.2014.047

  1547

  PDF: 908

  HTML: 1963

  Figure: 170

  Tables: 185

  ALL revision 1: 191

  response to reviewer: 180

• Successful management of pregnancy and hepatic toxicity in a CML female patient treated with nilotinib : a case report and a review

  Domenico Santorsola, Elisabetta Abruzzese

  e2015020

  2015-02-12

  https://doi.org/10.4084/mjhid.2015.020

  2012

  PDF: 1221

  HTML: 1628